secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071387
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Q1 net loss $28.5M; ELVN-001 44% MMR rate at 24 weeks, cash $290M
-------------------------------------------------------------------------

- Net loss of $28.5M for Q1 2025 vs $22.7M Q1 2024; R&D expenses $24.9M.
- Cash, equivalents and marketable securities $289.6M; runway into late 2027.
- ELVN-001 Phase 1 ENABLE: 44% (16/36) cumulative MMR by 24 weeks, well-tolerated, 74 patients.
- Strategic alternatives for ELVN-002 program; not pursued beyond 2025 to extend cash runway.
- Updated ELVN-001 data to be presented at EHA Congress in June; webcast June 13.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000095017025071387/0000950170-25-071387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000095017025071387/elvn-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer